Sotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) P/B ratio
As of 5 November 2026, Sotera Health Company (SHC) trades at a P/B ratio of 6.2×. Over the past ten years it has ranged from 0.0× (December 2020) to 16.2× (March 2021); the current reading is higher than 7% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 8.3× | (13.49%) |
| FY2024 | 9.6× | (9.93%) |
| FY2023 | 10.6× | 59.23% |
| FY2022 | 6.7× | (40.62%) |
| FY2021 | 11.2× | (26.67%) |
| FY2020 | 15.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 7.2× | (5.36%) |
| Jun 2026 | 7.6× | 16.12% |
| Mar 2026 | 6.6× | (20.60%) |
| Dec 2025 | 8.3× | 1.82% |
| 24 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 1.4× |
| GRAL GRAIL, Inc. compare | 2.4× |
| NEO NeoGenomics, Inc. compare | 2.7× |
| QGEN QIAGEN N.V. compare | 3.1× |
| RDNT RadNet, Inc. compare | 4.4× |
| SHC Sotera Health Company | 6.2× |
| CDNA CareDx, Inc. compare | 8.6× |
| BLLN BillionToOne, Inc. compare | 9.9× |
| ADPT Adaptive Biotechnologies Corporation compare | 23.5× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement